Oncimmune Holdings Financials
| ONC Stock | 1.14 0.23 16.79% |
Oncimmune | Select Account or Indicator |
Please note, the presentation of Oncimmune Holdings' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oncimmune Holdings' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Oncimmune Holdings' management manipulating its earnings.
Oncimmune Holdings Stock Summary
Oncimmune Holdings competes with Hilton Food, Molson Coors, Smithson Investment, Grieg Seafood, and Hansa Investment. Oncimmune Holdings is entity of United Kingdom. It is traded as Stock on LSE exchange.| Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB00BYQ94H38 |
| Business Address | 1 Park Row, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.oncimmune.com |
| Phone | 44 1157 840 500 |
You should never invest in Oncimmune Holdings without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Oncimmune Stock, because this is throwing your money away. Analyzing the key information contained in Oncimmune Holdings' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Oncimmune Holdings Key Financial Ratios
There are many critical financial ratios that Oncimmune Holdings' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Oncimmune Holdings plc reports annually and quarterly.| Revenue | 2.74 M | ||||
| Gross Profit | 1.23 M | ||||
| EBITDA | (3 M) | ||||
| Net Income | (4.11 M) | ||||
| Total Asset | 4.9 M |
Oncimmune Holdings Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 24.3M | 17.3M | 8.4M | 4.9M | 5.6M | 9.8M | |
| Other Current Liab | 1.2M | 6K | 722K | 693K | 797.0K | 644.0K | |
| Net Debt | 837K | 8.2M | 2.1M | 4.3M | 4.9M | 5.2M | |
| Retained Earnings | (70.1M) | (79.6M) | (42.5M) | (46.8M) | (42.1M) | (44.2M) | |
| Accounts Payable | 768K | 2.0M | 172K | 150K | 172.5K | 163.9K | |
| Cash | 8.6M | 2.5M | 3.2M | 846K | 972.9K | 924.3K | |
| Other Current Assets | 427K | 7.0M | 2.1M | 770K | 885.5K | 1.0M | |
| Total Liab | 19.1M | 20.0M | 7.8M | 7.3M | 8.4M | 7.1M | |
| Total Current Assets | 16.1M | 10.0M | 5.6M | 1.9M | 2.1M | 2.0M | |
| Common Stock | 635K | 691K | 695K | 741K | 852.2K | 490.8K | |
| Inventory | 143K | 413K | 235K | 238K | 273.7K | 199.9K | |
| Short Term Debt | 2.6M | 7.9M | 332K | 1.8M | 2.1M | 1.7M | |
| Net Tangible Assets | 5.4M | (2.6M) | (467K) | (7.5M) | (6.8M) | (6.4M) | |
| Long Term Debt | 6.2M | 2.4M | 4.9M | 3.3M | 3.8M | 3.4M | |
| Net Receivables | 6.9M | 1.7M | 1.9M | 311K | 357.7K | 339.8K | |
| Short Long Term Debt | 2.2M | 7.5M | 258K | 1.8M | 2.0M | 1.6M | |
| Other Assets | 356K | 937K | 927K | 1.0 | 1.15 | 1.09 | |
| Intangible Assets | 4.1M | 3.2M | 483K | 391K | 449.7K | 427.2K | |
| Net Invested Capital | 13.7M | 7.2M | 5.8M | 2.7M | 2.4M | 2.3M | |
| Net Working Capital | 6.3M | (5.1M) | 4.1M | (818K) | (736.2K) | (699.4K) | |
| Capital Stock | 635K | 691K | 695K | 741K | 852.2K | 758.3K |
Oncimmune Holdings Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 954K | 943K | 2.0M | 711K | 817.7K | 656.3K | |
| Total Revenue | 3.7M | 3.9M | 1.2M | 2.7M | 3.1M | 3.3M | |
| Gross Profit | 2.9M | 1.5M | 792K | 1.2M | 1.4M | 769.5K | |
| Operating Income | (5.1M) | (8.6M) | (4.2M) | (3.2M) | (2.9M) | (3.0M) | |
| Ebit | (5.2M) | (7.4M) | (5.4M) | (3.3M) | (2.9M) | (3.1M) | |
| Research Development | 1.5M | 1.7M | 1.6M | 1.5M | 1.3M | 0.0 | |
| Ebitda | (4.5M) | (7.2M) | (4.4M) | (3.0M) | (2.7M) | (2.8M) | |
| Cost Of Revenue | 865K | 2.4M | 360K | 1.5M | 1.7M | 1.8M | |
| Income Before Tax | (5.7M) | (9.5M) | (5.9M) | (4.0M) | (3.6M) | (3.8M) | |
| Net Income | (4.6M) | (9.5M) | 4.1M | (3.6M) | (3.3M) | (3.4M) | |
| Income Tax Expense | (1.1M) | (17K) | 223K | (477K) | (429.3K) | (450.8K) | |
| Tax Provision | (1.1M) | (17K) | 223K | (477K) | (548.6K) | (576.0K) | |
| Net Interest Income | (551K) | (943K) | (1.8M) | (694K) | (624.6K) | (655.8K) | |
| Interest Income | 111K | 403K | 0.0 | 17K | 19.6K | 18.6K |
Oncimmune Holdings Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Oncimmune Holdings plc. It measures of how well Oncimmune is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Oncimmune Holdings brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Oncimmune had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Oncimmune Holdings has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 31K | (270K) | 158K | (3K) | (3.5K) | (3.6K) | |
| Change In Cash | 4.4M | (6.1M) | 1.8M | (2.4M) | (2.1M) | (2.0M) | |
| Free Cash Flow | (5.6M) | (6.7M) | (6.8M) | (3.4M) | (3.1M) | (3.2M) | |
| Depreciation | 740K | 1.4M | 981K | 263K | 302.5K | 437.6K | |
| Other Non Cash Items | 727K | 943K | (416K) | 72K | 64.8K | 61.6K | |
| Capital Expenditures | 1.1M | 504K | 31K | 9K | 10.4K | 9.8K | |
| Net Income | (5.7M) | (9.5M) | (6.2M) | (4.1M) | (3.7M) | (3.9M) | |
| End Period Cash Flow | 8.6M | 2.5M | 3.2M | 846K | 761.4K | 723.3K | |
| Change To Netincome | 353K | (835K) | 326K | 2.3M | 2.7M | 2.8M | |
| Investments | (856K) | (504K) | 11.6M | 1.2M | 1.3M | 1.3M |
Oncimmune Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncimmune Holdings's current stock value. Our valuation model uses many indicators to compare Oncimmune Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncimmune Holdings competition to find correlations between indicators driving Oncimmune Holdings's intrinsic value. More Info.Oncimmune Holdings plc is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncimmune Holdings' earnings, one of the primary drivers of an investment's value.Oncimmune Holdings plc Systematic Risk
Oncimmune Holdings' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oncimmune Holdings volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Oncimmune Holdings plc correlated with the market. If Beta is less than 0 Oncimmune Holdings generally moves in the opposite direction as compared to the market. If Oncimmune Holdings Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oncimmune Holdings plc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oncimmune Holdings is generally in the same direction as the market. If Beta > 1 Oncimmune Holdings moves generally in the same direction as, but more than the movement of the benchmark.
Oncimmune Holdings plc Total Assets Over Time
Oncimmune Holdings March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oncimmune Holdings help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oncimmune Holdings plc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oncimmune Holdings plc based on widely used predictive technical indicators. In general, we focus on analyzing Oncimmune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oncimmune Holdings's daily price indicators and compare them against related drivers.
| Information Ratio | (0.31) | |||
| Maximum Drawdown | 49.22 | |||
| Value At Risk | (25.16) | |||
| Potential Upside | 9.68 |
Complementary Tools for Oncimmune Stock analysis
When running Oncimmune Holdings' price analysis, check to measure Oncimmune Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncimmune Holdings is operating at the current time. Most of Oncimmune Holdings' value examination focuses on studying past and present price action to predict the probability of Oncimmune Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncimmune Holdings' price. Additionally, you may evaluate how the addition of Oncimmune Holdings to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |